Open Access

ARTICLE

Disitamab Vedotin in HER2-Positive and HER2-Low Breast Cancer: A Multicenter Retrospective Analysis

Xizhou Zhang^1,#, Zetao Zhang^1,#, Jianguang Lin², Jiarong Yi³, Xuxiazi Zou³, Jikun Feng³, Guangsheng Huang¹, Bingfeng Chen¹, Junxi Long¹, Fengjia Wu³, Feng Ye^3,*, Haoming Wu^1,*

1 The Breast Center, Cancer Hospital of Shantou University Medical College, Guangdong Provincial Key Laboratory of Breast Cancer Diagnosis and Treatment, Shantou, 515031, China
2 Department of Oncology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, China
3 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China

* Corresponding Authors: Feng Ye. Email: ; Haoming Wu. Email:
# These authors contributed equally to this work

(This article belongs to the Special Issue: Breast Cancer Biomarkers and Drug Targets Discoveries Towards a More Personalized Treatment Setting)

Oncology Research 2025, 33(9), 2529-2547. https://doi.org/10.32604/or.2025.065029

Received 01 March 2025; Accepted 05 June 2025; Issue published 28 August 2025

Abstract

Background: Breast cancer remains a leading cause of morbidity and mortality among women worldwide, with significant geographic disparities in its impact. While human epidermal growth factor receptor 2 (HER2)-targeted therapies, such as trastuzumab, have improved outcomes for HER2-positive breast cancer, challenges like therapy resistance persist, highlighting the need for novel treatments. Recent developments in antibody-drug conjugates (ADCs), particularly disitamab vedotin (RC48), show promising efficacy in targeting both HER2-positive and HER2-low expression tumors, warranting further investigation through real-world studies to assess its broader clinical applicability. Method: This retrospective, multicenter observational study evaluated the real-world efficacy and safety of RC48 in patients with HER2-positive or HER2-low breast cancer across three medical centers in China. Patient demographic characteristics, treatment patterns, sequential use of ADCs, and treatment-related adverse events were recorded and analyzed. Result: The median progression-free survival (mPFS) for the overall population (n = 96) was 4.31 months, with HER2-positive patients demonstrating significantly longer mPFS (5.26 months) compared to HER2-low patients (3.45 months; p = 0.044), while subgroup analyses revealed no significant differences in mPFS based on estrogen receptor (ER), progesterone receptor (PR), or hormone receptor (HR) status. Safety data indicated that adverse events were consistent with prior reports, with no new safety concerns identified during the study period. Conclusion: This real-world study demonstrates the efficacy of RC48 in both HER2-positive and HER2-low breast cancer. Notably, combination therapy significantly improved outcomes in HER2-low patients.

---

Keywords

---